Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. That said, here are three small-cap stocks to avoid and some other investments you should consider instead.
Gibraltar (ROCK)
Market Cap: $1.17 billion
Gibraltar (NASDAQ: ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Does ROCK Worry Us?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.1% annually over the last two years
- Earnings per share have dipped by 9.1% annually over the past two years, which is concerning because stock prices follow EPS over the long term
- 7× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Gibraltar is trading at $44.28 per share, or 10.9x forward P/E. Read our free research report to see why you should think twice about including ROCK in your portfolio.
QuidelOrtho (QDEL)
Market Cap: $960.8 million
Born from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (NASDAQ: QDEL) develops and manufactures diagnostic testing solutions for healthcare providers, from rapid point-of-care tests to complex laboratory instruments and systems.
Why Should You Sell QDEL?
- Underwhelming constant currency revenue performance over the past two years suggests its product offering at current prices doesn’t resonate with customers
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 23 percentage points
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
QuidelOrtho’s stock price of $13.62 implies a valuation ratio of 6.5x forward P/E. Check out our free in-depth research report to learn more about why QDEL doesn’t pass our bar.
Amdocs (DOX)
Market Cap: $5.95 billion
Powering the digital experiences of approximately 400 communications companies worldwide, Amdocs (NASDAQ: DOX) provides software and services that help telecommunications and media companies manage customer relationships, monetize services, and automate network operations.
Why Does DOX Fall Short?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.6% annually over the last two years
- Estimated sales growth of 3.1% for the next 12 months is soft and implies weaker demand
- Earnings growth over the last two years fell short of the peer group average as its EPS only increased by 8.1% annually
At $51.90 per share, Amdocs trades at 6.4x forward P/E. Dive into our free research report to see why there are better opportunities than DOX.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
